<code id='E7A295E8AC'></code><style id='E7A295E8AC'></style>
    • <acronym id='E7A295E8AC'></acronym>
      <center id='E7A295E8AC'><center id='E7A295E8AC'><tfoot id='E7A295E8AC'></tfoot></center><abbr id='E7A295E8AC'><dir id='E7A295E8AC'><tfoot id='E7A295E8AC'></tfoot><noframes id='E7A295E8AC'>

    • <optgroup id='E7A295E8AC'><strike id='E7A295E8AC'><sup id='E7A295E8AC'></sup></strike><code id='E7A295E8AC'></code></optgroup>
        1. <b id='E7A295E8AC'><label id='E7A295E8AC'><select id='E7A295E8AC'><dt id='E7A295E8AC'><span id='E7A295E8AC'></span></dt></select></label></b><u id='E7A295E8AC'></u>
          <i id='E7A295E8AC'><strike id='E7A295E8AC'><tt id='E7A295E8AC'><pre id='E7A295E8AC'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:7
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Readout LOUD podcast: Venture capital turmoil, obesity drug competition
          Readout LOUD podcast: Venture capital turmoil, obesity drug competition

          Whyareaddictiontreatmentssohardtoget?Cansmallcompaniescompeteinobesity?Andsincewhenis“SeriesE”athing

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne